AIM: To ascertain pathologic stage as a prognostic indicator for rectal cancer patients receiving preoperative chemoradiotherapy (PCRT). METHODS: Patients with mid- and low rectal carcinoma (magnetic resonance imaging - based clinical stage II or III) between 2000 and 2009 and treated with curative radical resection were identified. Patients were divided into two groups: PCRT and No-PCRT. Recurrence-free survival (RFS) was examined according to pathologic stage and addition of adjuvant treatment. RESULTS: Overall, 894 patients were identified. Of these, 500 patients received PCRT. Adjuvant chemotherapy was delivered to 81.5% of the No-PCRT and 94.8% of the PCRT patients. Adjuvant radiotherapy was given to 29.4% of the patients in the No PCRT group. The 5-year RFS for the No-PCRT group was 92.6% for Stage I, 83.3% for Stage II, and 72.9% for Stage III. The 5-year RFS for the PCRT group was 95.2% for yp Stage 0, 91.7% for yp Stage I, 73.9% for yp Stage II, and 50.7% for yp Stage III. CONCLUSION: Pathologic stage can predict prognosis in PCRT patients. 5-year RFS is significantly lower among PCRT patients than No-PCRT patients in pathologic stage II and III. These results should be taken into account when considering adjuvant treatment for patients treated with PCRT.
AIM: To ascertain pathologic stage as a prognostic indicator for rectal cancerpatients receiving preoperative chemoradiotherapy (PCRT). METHODS:Patients with mid- and low rectal carcinoma (magnetic resonance imaging - based clinical stage II or III) between 2000 and 2009 and treated with curative radical resection were identified. Patients were divided into two groups: PCRT and No-PCRT. Recurrence-free survival (RFS) was examined according to pathologic stage and addition of adjuvant treatment. RESULTS: Overall, 894 patients were identified. Of these, 500 patients received PCRT. Adjuvant chemotherapy was delivered to 81.5% of the No-PCRT and 94.8% of the PCRT patients. Adjuvant radiotherapy was given to 29.4% of the patients in the No PCRT group. The 5-year RFS for the No-PCRT group was 92.6% for Stage I, 83.3% for Stage II, and 72.9% for Stage III. The 5-year RFS for the PCRT group was 95.2% for yp Stage 0, 91.7% for yp Stage I, 73.9% for yp Stage II, and 50.7% for yp Stage III. CONCLUSION: Pathologic stage can predict prognosis in PCRT patients. 5-year RFS is significantly lower among PCRT patients than No-PCRT patients in pathologic stage II and III. These results should be taken into account when considering adjuvant treatment for patients treated with PCRT.
Entities:
Keywords:
Chemoradiotherapy; Pathologic stage; Preoperative; Prognosis; Rectal cancer
Authors: A K Chan; A O Wong; J Langevin; D Jenken; J Heine; D Buie; D R Johnson Journal: Int J Radiat Oncol Biol Phys Date: 2000-10-01 Impact factor: 7.038
Authors: Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab Journal: N Engl J Med Date: 2004-10-21 Impact factor: 91.245
Authors: B Michael Ghadimi; Marian Grade; Michael J Difilippantonio; Sudhir Varma; Richard Simon; Cristina Montagna; Laszlo Füzesi; Claus Langer; Heinz Becker; Torsten Liersch; Thomas Ried Journal: J Clin Oncol Date: 2005-03-20 Impact factor: 44.544
Authors: N A Janjan; C Crane; B W Feig; K Cleary; R Dubrow; S Curley; J N Vauthey; P Lynch; L M Ellis; R Wolff; R Lenzi; J Abbruzzese; R Pazdur; P M Hoff; P Allen; T Brown; J Skibber Journal: Am J Clin Oncol Date: 2001-04 Impact factor: 2.339
Authors: George Theodoropoulos; W E Wise; A Padmanabhan; B A Kerner; C W Taylor; P S Aguilar; K S Khanduja Journal: Dis Colon Rectum Date: 2002-07 Impact factor: 4.585
Authors: Seong-A Jeong; In Ja Park; Seung Mo Hong; Jun Woo Bong; Hye Yoon Choi; Ji Hyun Seo; Hyong Eun Kim; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim Journal: Ann Surg Treat Res Date: 2018-01-30 Impact factor: 1.859
Authors: Azadeh Azizian; Ingo Epping; Frank Kramer; Peter Jo; Markus Bernhardt; Julia Kitz; Gabriela Salinas; Hendrik A Wolff; Marian Grade; Tim Beißbarth; B Michael Ghadimi; Jochen Gaedcke Journal: Int J Mol Sci Date: 2016-04-15 Impact factor: 5.923